To assess the feasibility and potential efficacy of the RAD regimen for treating patients with primary central nervous system lymphoma (PCNSL).
Conducted a single-arm, phase 1b study across multiple centers
Evaluated the feasibility of the RAD regimen in patients with PCNSL
The RAD regimen was deemed feasible for treating PCNSL patients
Indicators suggest potential as a therapeutic option
Abstract
The RAD regimen is feasible for treating PCNSL patients and shows potential as a therapeutic option. Further large-scale trials are needed to confirm its clinical efficacy.